公开(公告)号：US20240124416A1

公开(公告)日：2024-04-18

申请号：US18513418

申请日：2023-11-17

申请人： Escient Pharmaceuticals, Inc.

发明人： Marion LANIER ,  Marcus BOEHM ,  Liming HUANG ,  Esther MARTINBOROUGH ,  Marcos SAINZ ,  Brandon SELFRIDGE ,  Adam YEAGER

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

摘要： Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240351987A1

公开(公告)日：2024-10-24

申请号：US18615563

申请日：2024-03-25

申请人： Escient Pharmaceuticals, Inc.

发明人： Marion LANIER ,  Marcus BOEHM ,  Liming HUANG ,  Esther MARTINBOROUGH ,  Marcos SAINZ ,  Brandon SELFRIDGE ,  Adam YEAGER

IPC分类号： C07D215/44 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D215/44 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

摘要： Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240124414A1

公开(公告)日：2024-04-18

申请号：US18513387

申请日：2023-11-17

申请人： Escient Pharmaceuticals, Inc.

发明人： Marion LANIER ,  Marcus BOEHM ,  Liming HUANG ,  Esther MARTINBOROUGH ,  Marcos SAINZ ,  Brandon SELFRIDGE ,  Adam YEAGER

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

摘要： Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240254089A1

公开(公告)日：2024-08-01

申请号：US18245700

申请日：2021-09-16

申请人： ESCIENT PHARMACEUTICALS, INC.

发明人： Brandon SELFRIDGE ,  Liming HUANG ,  Adam YEAGER ,  Marcos SAINZ ,  Marion LANIER ,  Esther MARTINBOROUGH ,  Marcus BOEHM

IPC分类号： C07D231/56 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

CPC分类号： C07D231/56 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

摘要： Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4-dependent condition more specifically, by contacting MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein E, Q, W, Z, R1, R2, R3, and R4 are as defined herein. Pharmaceutical compositions containing such compounds, as well as compounds themselves, are also provided.

公开(公告)号：US20240124415A1

公开(公告)日：2024-04-18

申请号：US18513400

申请日：2023-11-17

申请人： Escient Pharmaceuticals, Inc.

发明人： Marion LANIER ,  Marcus BOEHM ,  Liming HUANG ,  Esther MARTINBOROUGH ,  Marcos SAINZ ,  Brandon SELFRIDGE ,  Adam YEAGER

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

摘要： Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.